Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
![GlobeNewswire](../../../Content/images/providers/GN.png)
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: GlobeNewswire
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamicsData support further clinical evaluation of MP0317 in combination settings ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics, today announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, held in Chicago, IL, USA. MP0317 is a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment (
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitGlobeNewswire
- Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024GlobeNewswire
- Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 [Yahoo! Finance]Yahoo! Finance
- Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024GlobeNewswire
MOLN
Sec Filings
- 6/14/24 - Form 6-K
- 6/11/24 - Form 6-K
- 6/3/24 - Form 6-K
- MOLN's page on the SEC website